 Cue Biopharma NASDAQ:CUE was upgraded by equities research analysts at BidaskClub from a buy rating to a strong-buy rating in a research note issued to investors on Saturday, BidAskClub reports. A number of other equities research analysts have also recently issued reports on CUE. Zacks Investment Research raised shares of Cue Biopharma from a hold ... 